» Articles » PMID: 21782458

Structural Basis of Substrate Methylation and Inhibition of SMYD2

Overview
Journal Structure
Publisher Cell Press
Date 2011 Jul 26
PMID 21782458
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Protein lysine methyltransferases are important regulators of epigenetic signaling. These enzymes catalyze the transfer of donor methyl groups from S-adenosylmethionine to specific acceptor lysines on histones, leading to changes in chromatin structure and transcriptional regulation. These enzymes also methylate nonhistone protein substrates, revealing an additional mechanism to regulate cellular physiology. The oncogenic protein SMYD2 represses the functional activities of the tumor suppressor proteins p53 and Rb, making it an attractive drug target. Here we report the discovery of AZ505, a potent and selective inhibitor of SMYD2 that was identified from a high throughput chemical screen. We also present the crystal structures of SMYD2 with p53 substrate and product peptides, and notably, in complex with AZ505. This substrate competitive inhibitor is bound in the peptide binding groove of SMYD2. These results have implications for the development of SMYD2 inhibitors, and indicate the potential for developing novel therapies targeting this target class.

Citing Articles

Lysine and arginine methylation of transcription factors.

Giaimo B, Ferrante F, Borggrefe T Cell Mol Life Sci. 2024; 82(1):5.

PMID: 39680066 PMC: 11649617. DOI: 10.1007/s00018-024-05531-6.


A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.

Craig O, Lee S, Pilcher C, Saoud R, Abdirahman S, Salazar C NAR Genom Bioinform. 2024; 6(3):lqae096.

PMID: 39184376 PMC: 11344246. DOI: 10.1093/nargab/lqae096.


The modification role and tumor association with a methyltransferase: KMT2C.

Jiao Y, Lv Y, Liu M, Liu Y, Han M, Xiong X Front Immunol. 2024; 15:1444923.

PMID: 39165358 PMC: 11333232. DOI: 10.3389/fimmu.2024.1444923.


SETDB1 as a cancer target: challenges and perspectives in drug design.

Hassanie H, Penteado A, de Almeida L, Calil R, da Silva Emery F, Costa-Lotufo L RSC Med Chem. 2024; 15(5):1424-1451.

PMID: 38799223 PMC: 11113007. DOI: 10.1039/d3md00366c.


Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.

Li J, Hong Z, Zhang J, Zheng S, Wan F, Liu Z Oncogene. 2024; 43(10):744-757.

PMID: 38243079 DOI: 10.1038/s41388-024-02945-1.